Please tell us about your clinical experience. How many patients with multiple myeloma do you treat? What is the standard of care?

Current treatment interventions are able to place a patient in remission, but how likely are patients to relapse?

How much of a need is there for novel treatments in this space ? Where do you see ciltacabtagene autoleucel fitting, compared to standard of care? What other upcoming therapies are you excited about? How poor is the prognosis for patients with MM?

Can you please discuss the Two-Year Analysis of CARTITUDE-1? It reported responses to cilta-cel for “up to 2 years” in most subgroups of patients with heavily pretreated RRMM.Adjusted comparisons in a 113 patient cohort showed improvements for cilta-cel vs. RWCP for ORR (RR=4.43), ≥CR (RR=568.92), PFS (HR=0.15) and OS (HR=0.38) in triple-class exposed RRMM.

Patients treated with cilta-cel experienced more adverse events , including Grade 3/4 events, as compared to RWCP. How concerned would you be when weighing in on cilta-cel ?

Could you please draw parallels to Bristol Myers' Abecma? Demand for the therapy is rumored to have outstripped capacity, have you seen this in clinic as well? How likely is Legend to outcompete the likes of Bristol Myers, Novartis, Gilead Sciences and others in the field?

The key challenge is the production of lentiviral vectors that are crucial to cell therapy. Can you tell us more about this aspect?

Based on the available knowledge on cilta-cel , what’s your conclusion about its safety and efficacy profile? How likely would you be to have patients treated with it?